OX40 triggering also helps overcome tumor-induced immune tolerization, making it a promising approach for enhancing cancer immunotherapy.92 OX40 agonists, which stimulate the OX40-OX40L pathway, are being studied as potential cancer therapies. Here, TNFRSF4 is linked to neoplasm.